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High Prevalence of Germline CDKN2A Mutations in Slovenian Cutaneous 
Malignant Melanoma Families
Aim To prospectively determine the prevalence of germline CDKN2A 
mutations in the Slovenian cutaneous malignant melanoma (CMM) 
families.
Methods From January 2001 till the end of 2003 we prospectively 
screened 19 individuals from 11 CMM families, as well as 3 children 
with CMM aged from 6 to 13 years, with a negative family history.
Results Five distinct mutations were detected in 5 out of 11 screened 
families (10/19 individuals) and a previously recognized polymorphism 
was detected in a single family. Detected mutations were functionally 
deleterious (T281A, G68A, G301T, G71C and IVS – 1g > a). No mu-
tations could be detected in 3 children.
Conclusions The prevalence of CDKN2A mutations among Slovenian 
CMM families was high, indicating the need for genetic counseling.
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Clinical Science
The CDKN2A gene is the most common cause of inherit-
ed cutaneous malignant melanoma (CMM) (1). The pres-
ence and frequency of CDKN2A gene mutations in familial 
CMM vary considerably in different populations. Yakobson 
(2) did not find even a single case of germline CDKN2A mu-
tation among 31 Israeli CMM families. However, Mantel-
li (3) reported a high prevalence of 34% of the germline CD-
KN2A mutations in his study of 62 Italian CMM families. 
Overall, the CDKN2A mutations were detected in approxi-
mately 20% of the tested CMM families (1).
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The aim of our study was to prospectively de-
termine the prevalence of germline CDKN2A 
mutations in the Slovenian CMM families.
Patients and Methods
Patients
From January 2001 until the end of 2003, 11 pa-
tients with CMM and the history of at least two 
affected family members were treated at the Mel-
anoma Clinic of the Institute of Oncology, Lju-
bljana. All these 11 index patients and their 8 
healthy relatives who agreed to participate in the 
study were referred to the Familial Cancer Clinic 
for genetic counseling and testing (Table 1).
Additionally, 3 children with CMM aged 
from 6 to 13 years and with negative family his-
tory were also referred to the Familial Cancer 
Clinic for Genetic Testing. We did not exam-
ine the children’s relatives since children were all 
mutation negative.
Methods
Genomic DNA of the patients was extracted 
from the peripheral blood using the salting-out 
procedure (4). Each of the three exons, togeth-
er with their splicing sites, was amplified in the 
polymerase chain reaction (PCR). The fragment 
with the exon 1 included also a part of the pro-
moter, the fragment with the exon 3 included a 
part of 3′-UTR, and on the other side, a part of 
the intron 2, included the possible mutation spot 
IVS2-105. The PCR reaction mixture, thermal 
cycling conditions, and primers were used as de-
scribed elsewhere (5). Briefly, AmpliTaq Gold 
polymerase was used for amplification in 32 ther-
mal cycles in all reactions. The presence of ampli-
cons was verified by a 2% agarose gel electropho-
resis.
For PCR fragments, the purification QIA-
quick PCR Purification Kit (Qiagen, Hilden, 
Germany) was used. The sequencing was per-
formed in both directions by the same forward 
and reverse primers that were used for the ini-
tial PCR amplification. Sequencing reaction was 
performed using the ABI PRISM Big Dye Ter-
minator Cycle Sequencing Kit (Applied Biosys-
tems, Norwalk, CT, USA). The products were 
analyzed on the ABI PRISM 310 DNA genetic 
analyzer (Applied Biosystems).
The obtained nucleotide sequences were 
compared to the genomic reference sequence in 
GenBank, accession number AF527803.
We used t test for comparison of the mean 
values between groups.
Results
Five distinct mutations (T281A, G68A, G301T, 
G71C and IVS – 1g > a) were detected in 5 out 
of 11 screened families (10/19 individuals) (Ta-
ble 1). Additionally, a previously recognized poly-
morphism (A148T) was detected in one family. 
Five out of 8 relatives were also tested positive. 
In the family No. 2 (T281A mutation), all 4 rel-
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primary melanoma








No. of tested family members/ 
No. of mutation carriers
1 female 27 3 two sisters    –   –
2 female 57 5 son, nephew T281A L94Q 4/4
3 female 36 1 mother    –   –
4 male 40 4 mother, sister G68A G23D 2/1
5 female 44 1 mother    –   –
6 female 35 1 mother    –   –
7 female 21 3 mother IVS – 1g > a 1/0
8 female 50 3 mother G301T G101W 1/0
9 male 62 1 nephew    –   –
10 female 35 6 mother G71C R24P
11 female 62 1 brother G442A A148T
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atives were tested positive. Although clinically 
healthy (without CMM) at the time of the test, 
one already developed CMM at the age of 41.
All 5 families with the detected CDKN2A 
gene mutation had an index patient with multi-
ple primary melanomas. There was only one fam-
ily (No. 1) with multiple primary melanomas 
and three affected family members without the 
CDKN2A gene mutation.
There was no statistically significant differ-
ence in the mean age at diagnosis of index pa-
tients between the group of families with the 
CDKN2A gene mutation (40.6 years, range 21-
57) and the group without the CDKN2A gene 
mutation (40.8 years, range 27-62) (P<0.05).
No mutations were detected in all three chil-
dren (all <14 years) with CMM and a negative 
family history.
Discussion
The presence and frequency of CDKN2A gene 
mutations in familial CMM vary considerably 
among different continents and even among dif-
ferent countries on the same continent (1). Our 
study was the first study of the Slovenian popu-
lation. Slovenia is a Central European country 
with two million inhabitants and an incidence 
of CMM of 11.3 per year. We found 5 different 
CDKN2A gene mutations in 5 out of 11 Slove-
nian CMM families (10/19 patients). This is a 
surprisingly high percentage of CDKN2A gene 
mutations since this was a clinic-based popula-
tion. There were 3 affected family members in 3 
separate families and 2 in other 8 families. A pos-
sible explanation for the high percentage in our 
population is the fact that the percentage of mul-
tiple primary melanomas in our CMM families 
was very high, 6 out of 11. In fact, CDKN2A 
gene mutations were detected only in CMM 
families with multiple primary melanomas (5/6). 
Multiple primary tumors are one of the key fea-
tures of the genetic cancer syndromes. Hashe-
mi (6) reported that 9 of 80 (11%) patients with 
multiple primary melanomas had the CDKN2A 
gene mutations. Seven of these patients belonged 
to CMM families. Additionally, Auroy et al (7) 
reported a series of 100 patients with multiple 
primary melanomas and a negative family histo-
ry. The CDKN2A gene mutations were detected 
in 9 of them.
Mutational analysis was negative in all 3 chil-
dren in our study (aged 6, 8, and 13 years), who 
had a negative melanoma family history. The rea-
son why we included them in the study was the 
fact that the early age of onset is also one of the 
hallmarks of genetic cancer syndromes. In fact, 
the American Society of Clinical Oncology rec-
ommends that cancer-predisposition testing 
should be offered when the person has a strong 
family history or a very early age of cancer onset 
(8). The results of these 3 children are in agree-
ment with the report by Whitemann et al (9) 
who found a single germline CDKN2A gene 
mutation in a large group of 61 children. Tsao et 
al (10), who analyzed the prevalence of germline 
CDKN2A gene mutations in patients with an 
early-onset CMM, also concluded that these mu-
tations were not common and that, at the mo-
ment, genetic testing based solely on the age of 
onset could not be warranted.
All of the mutations detected in our series 
of patients were functionally deleterious. Two 
of the disease-causing mutations were novel and 
one of them was already described elsewhere (5).
Nucleotide substitution g.281T>A in the 
exon 2 causes the amino acid change L94Q. Its 
functional importance was presumed from the 
protein p16 structure. Hydrophobic properties 
of leucine are assumed to be important in keep-
ing the correct 3-dimensional structure of the 
protein p16, which is probably needed in assur-
ing the effectiveness of the binding site (5). The 
L94Q mutation co-segregates with the disease in 
the family.
IVS1-1g > a is a novel acceptor splice site 
mutation. A previously described substitution 
IVS1-1g > c in a family with melanomas, neuro-
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fibromas, and multiple dysplastic nevi was dem-
onstrated to lead to skipping the entire exon 2 
in the proteins p16 and p14ARF. Both proteins 
were consequently inactive (11).
A g.68G>A mutation of the exon 1 in the 
CDKN2A gene causes the amino acid change 
G23D (12). This mutation was previously de-
scribed in one French and one Italian family, 
with the co-segregation of the mutation with 
the disease in one of the families (12,13). To our 
knowledge, the biochemical activity of the G23D 
mutants has not been assessed. However, glycine 
in this place is absolutely conserved in human 
and murine p16 analogues (14).
In addition to 5 detected mutations, one pa-
tient without identified disease-causing mutation 
from our study was found to be heterozygous for 
previously recognized single nucleotide polymor-
phism g.442G>A (A148T).
In conclusion, the prevalence of CDKN2A 
mutations appears to be high (approaching 50%) 
among Slovenian CMM families. Genetic coun-
seling is necessary for these families since they 
may benefit from preventive clinical programs.
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